title: Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
abstract: Low malignant potential serous tumours (LMPSTs) of the ovary represent an indolent disease, with an excellent prognosis in a majority of patients. Patients with recurrent LMPSTs tend to develop widespread disease with a mortality rate as high as 70%. These tumours tend to have a very poor response to standard chemotherapy, and the management of primary and recurrent disease beyond surgical resection is not well defined. The majority of LMPST have been reported to express oestrogen and progesterone hormone receptors. However, only three reported cases of antihormonal treatment in this setting, and only one using aromatase inhibitors (AI), have been previously reported. We herein report long-term complete remission of two patients with relapsed, chemotherapy-resistant LMPSTs, treated with long-term AI (anastrozole 1 mg daily) as per negative MRI and positron emission tomography scans. Our results warrant further investigation for the use of AIs for metastatic recurrent LMPSTs.
authors.affiliation: Department of Medical Oncology, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Khashayar
authors.initials: K
authors.lastname: Esfahani
authors.affiliation: Department of Medical Oncology, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Cristiano
authors.initials: C
authors.lastname: Ferrario
authors.affiliation: Department of Medical Oncology, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Philippe
authors.initials: P
authors.lastname: Le
authors.affiliation: Department of Medical Oncology, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Panasci
mesh_terms: D000328:Adult; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000378:metabolism; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009570:Nitriles / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012074:Remission Induction; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000556:secondary / Q000601:surgery*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; D000077384:Anastrozole